

# Stefanie Hayoz

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3480218/publications.pdf>

Version: 2024-02-01

75  
papers

1,833  
citations

331538

21  
h-index

289141

40  
g-index

79  
all docs

79  
docs citations

79  
times ranked

2809  
citing authors

#	ARTICLE	IF	CITATIONS
1	Generation and validation of a PET radiomics model that predicts survival in diffuse large B cell lymphoma treated with Râ€CHOP14: A SAKK 38/07 trial postâ€hoc analysis. <i>Hematological Oncology</i> , 2022, 40, 12-22.	0.8	13
2	Adherence to Contouring and Treatment Planning Requirements Within a Multicentric Trial: Results of the Quality Assurance of the SAKK 09/10 trial. <i>International Journal of Radiation Oncology Biology Physics</i> , 2022, 113, 80-91.	0.4	5
3	A Phase 1/2 Single-arm Clinical Trial of Recombinant Bacillus Calmette-GuÃ©rin (BCG) VPM1002BC Immunotherapy in Nonâ€muscle-invasive Bladder Cancer Recurrence After Conventional BCG Therapy: SAKK 06/14. <i>European Urology Oncology</i> , 2022, , .	2.6	10
4	Integration of Baseline Metabolic Parameters and Mutational Profiles Predicts Long-Term Response to First-Line Therapy in DLBCL Patients: A Post Hoc Analysis of the SAKK38/07 Study. <i>Cancers</i> , 2022, 14, 1018.	1.7	7
5	Prescription Patterns, Recurrence, and Toxicity Rates of Adjuvant Treatment for Stage III/IV Melanomaâ€”A Real World Single-Center Analysis. <i>Biology</i> , 2022, 11, 422.	1.3	4
6	Long-term outcomes of operable stage III NSCLC in the pre-immunotherapy era: results from a pooled analysis of the SAKK 16/96, SAKK 16/00, SAKK 16/01, and SAKK 16/08 trials. <i>ESMO Open</i> , 2022, 7, 100455.	2.0	11
7	Long-term benefit of lurbinectedin as palliative chemotherapy in progressive malignant pleural mesothelioma (MPM): final efficacy and translational data of the SAKK 17/16 study. <i>ESMO Open</i> , 2022, 7, 100446.	2.0	5
8	Outcome and Prognostic Factors of COVID-19 Infection in Swiss Cancer Patients: Final Results of SAKK 80/20 (CaSA). <i>Cancers</i> , 2022, 14, 2191.	1.7	2
9	SAKK 35/15: a phase 1 trial of obinutuzumab in combination with venetoclax in patients with previously untreated follicular lymphoma. <i>Blood Advances</i> , 2022, 6, 3911-3920.	2.5	4
10	Validation of the Decipher genomic classifier in patients receiving salvage radiotherapy without hormone therapy after radical prostatectomy â€” an ancillary study of the SAKK 09/10 randomized clinical trial. <i>Annals of Oncology</i> , 2022, 33, 950-958.	0.6	22
11	Prognostic value of POD24 validation in follicular lymphoma patients initially treated with chemotherapyâ€free regimens in a pooled analysis of three randomized trials of the Swiss Group for Clinical Cancer Research (SAKK). <i>British Journal of Haematology</i> , 2021, 192, 1031-1034.	1.2	14
12	Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): An update on 107 randomized trials and 19,805 patients, on behalf of MACH-NC Group. <i>Radiotherapy and Oncology</i> , 2021, 156, 281-293.	0.3	157
13	Chemotherapy and radiotherapy in locally advanced head and neck cancer: an individual patient data network meta-analysis. <i>Lancet Oncology</i> , The, 2021, 22, 727-736.	5.1	45
14	Pembrolizumab monotherapy for high-risk, non-muscle-invasive bladder cancer. <i>Lancet Oncology</i> , The, 2021, 22, e379.	5.1	0
15	Dose-intensified Versus Conventional-dose Salvage Radiotherapy for Biochemically Recurrent Prostate Cancer After Prostatectomy: The SAKK 09/10 Randomized Phase 3 Trial. <i>European Urology</i> , 2021, 80, 306-315.	0.9	64
16	LBA30 Single-dose carboplatin followed by involved-node radiotherapy as curative treatment for seminoma stage IIA/B: Efficacy results from the international multicenter phase II trial SAKK 01/10. <i>Annals of Oncology</i> , 2021, 32, S1305.	0.6	5
17	1279P The prognostic value of chemotherapy-induced neutropenia (CIN) in patients with advanced non-small cell lung cancer (NSCLC) in the era of chemoimmunotherapy (CIT). <i>Annals of Oncology</i> , 2021, 32, S996.	0.6	1
18	LBA26 Darolutamide maintenance in metastatic castration resistant prostate cancer (mCRPC) previously treated with novel hormonal agents (NHA) and non-progressive disease after subsequent treatment with a taxane: A randomized double-blind placebo-controlled phase II trial (SAKK 08/16). <i>Annals of Oncology</i> , 2021, 32, S1301-S1302.	0.6	1

#	ARTICLE	IF	CITATIONS
19	Tailored axillary surgery in patients with clinically node-positive breast cancer: Pre-planned feasibility substudy of TAXIS (OPBC-03, SAKK 23/16, IBCSG 57-18, ABCSG-53, GBG 101). <i>Breast</i> , 2021, 60, 98-110.	0.9	28
20	P30.01 Extended Resections for Advanced Stages T3/T4 NSCLC After Neoadjuvant Treatment: Conclusions of SAKK Pooled Analysis (16/96, 16/00, 16/01). <i>Journal of Thoracic Oncology</i> , 2021, 16, S1051.	0.5	0
21	Performance of a Genomic Classifier (GC) Within a Phase 3 Randomized Trial of Dose Escalated Salvage Radiotherapy (SRT) After Radical Prostatectomy (RP). <i>International Journal of Radiation Oncology Biology Physics</i> , 2021, 111, S49-S50.	0.4	1
22	P-227: Alternate day dosing of pomalidomide in patients with refractory/relapsed multiple myeloma (RRMM): Results of a multicenter, single arm phase 2 trial (SAKK 39/16 OptiPOM Study). <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2021, 21, S165.	0.2	0
23	In Regard to Qi et Al. <i>International Journal of Radiation Oncology Biology Physics</i> , 2020, 107, 224-225.	0.4	0
24	Anthropometric outcomes after one year of remote counselling of overweight and obese adults by dietitians. <i>Proceedings of the Nutrition Society</i> , 2020, 79, .	0.4	0
25	Prognostic models integrating quantitative parameters from baseline and interim positron emission computed tomography in patients with diffuse large B-cell lymphoma: post-hoc analysis from the SAKK38/07 clinical trial. <i>Hematological Oncology</i> , 2020, 38, 715-725.	0.8	14
26	Prolonged rituximab maintenance in follicular lymphoma patients: long-term results of the SAKK 35/03 randomized trial. <i>Blood Advances</i> , 2020, 4, 5951-5957.	2.5	9
27	575P TLD-1, a novel liposomal doxorubicin, in patients (pts) with advanced solid tumours: Dose escalation part of a multicenter open-label phase I trial (SAKK 65/16). <i>Annals of Oncology</i> , 2020, 31, S490.	0.6	1
28	126TiP Tailored axillary surgery with or without axillary lymph node dissection followed by radiotherapy in patients with clinically node-positive breast cancer (SAKK 23/16 / IBCSG 57-18 / ABCSG-53 / Tj ETQq00 0 rgBT /Overlock	0.6	1
29	Results of the phase I open label clinical trial SAKK 06/14 assessing safety of intravesical instillation of VPM1002BC, a recombinant mycobacterium <i>Bacillus Calmette Guérin</i> (BCG), in patients with non-muscle invasive bladder cancer and previous failure of conventional BCG therapy. <i>Oncolmmunology</i> , 2020, 9, 1748981.	2.1	19
30	Immunomodulatory drugs may overcome the negative prognostic role of active Th17 axis in follicular lymphoma: evidence from the SAKK35/10 trial. <i>British Journal of Haematology</i> , 2020, 190, e258-e261.	1.2	9
31	High thromboembolic event rate in patients with locally advanced oesophageal cancer during neoadjuvant therapy. An exploratory analysis of the prospective, randomised intergroup phase III trial SAKK 75/08. <i>BMC Cancer</i> , 2020, 20, 166.	1.1	2
32	Prognostic implications of the microenvironment for follicular lymphoma under immunomodulation therapy. <i>British Journal of Haematology</i> , 2020, 189, 707-717.	1.2	13
33	SAKK38/07 study: integration of baseline metabolic heterogeneity and metabolic tumor volume in DLBCL prognostic model. <i>Blood Advances</i> , 2020, 4, 1082-1092.	2.5	47
34	Risk Factors and Treatment Outcomes of 1,375 Patients with Testicular Leydig Cell Tumors: Analysis of Published Case Series Data. <i>Journal of Urology</i> , 2020, 203, 949-956.	0.2	30
35	Reply by Authors. <i>Journal of Urology</i> , 2020, 203, 956-956.	0.2	0
36	Surgical Outcomes After Neoadjuvant Chemoradiation Followed by Curative Surgery in Patients With Esophageal Cancer. <i>Annals of Surgery</i> , 2020, Publish Ahead of Print, .	2.1	3

#	ARTICLE	IF	CITATIONS
37	SAKK 35/15: A PHASE I TRIAL OF OBINUTUZUMAB IN COMBINATION WITH VENETOCLAX IN PREVIOUSLY UNTREATED FOLLICULAR LYMPHOMA PATIENTS. <i>Hematological Oncology</i> , 2019, 37, 118-119.	0.8	3
38	RE-AIM evaluation of a one-year trial of a combined educational and environmental workplace intervention to lower salt intake in Switzerland. <i>Preventive Medicine Reports</i> , 2019, 16, 100982.	0.8	12
39	Skeletal muscle mass correlates with increased toxicity during neoadjuvant radiochemotherapy in locally advanced esophageal cancer: A SAKK 75/08 substudy. <i>Radiation Oncology</i> , 2019, 14, 166.	1.2	28
40	Quality of Life After Total Mesorectal Excision and Rectal Replacement: Comparing Side-to-End, Colon J-Pouch and Straight Colorectal Reconstruction in a Randomized, Phase III Trial (SAKK 40/04). <i>Annals of Surgical Oncology</i> , 2019, 26, 3568-3576.	0.7	23
41	Short regimen of rituximab plus lenalidomide in follicular lymphoma patients in need of first-line therapy. <i>Blood</i> , 2019, 134, 353-362.	0.6	45
42	Clinical Outcome After Rectal Replacement With Side-to-End, Colon-J-Pouch, or Straight Colorectal Anastomosis Following Total Mesorectal Excision. <i>Annals of Surgery</i> , 2019, 269, 827-835.	2.1	46
43	PROGNOSTIC IMPLICATIONS OF THE MICROENVIRONMENT IN FOLLICULAR LYMPHOMA UNDER RITUXIMAB AND RITUXIMAB+LENALIDOMIDE THERAPY. A TRANSLATIONAL STUDY OF THE SAKK35/10 TRIAL. <i>Hematological Oncology</i> , 2019, 37, 149-151.	0.8	1
44	INTEGRATION BETWEEN METABOLIC TUMOUR VOLUME AND METABOLIC HETEROGENEITY PREDICTS OUTCOME OF DLBCL LYMPHOMA PATIENTS IN THE SAKK 38/07 STUDY COHORT. <i>Hematological Oncology</i> , 2019, 37, 77-78.	0.8	0
45	PREDICTIVE VALUE OF POD24 VALIDATION IN FOLLICULAR LYMPHOMA PATIENTS INITIALLY TREATED WITH CHEMOTHERAPYâ€FREE REGIMENS IN A POOLED ANALYSIS OF THREE RANDOMIZED TRIALS OF THE SWISS GROUP FOR CLINICAL CANCER RESEARCH (SAKK).. <i>Hematological Oncology</i> , 2019, 37, 111-112.	0.8	5
46	Effectiveness and Feasibility of a Remote Lifestyle Intervention by Dietitians for Overweight and Obese Adults: Pilot Study. <i>JMIR MHealth and UHealth</i> , 2019, 7, e12289.	1.8	44
47	Neoadjuvant chemotherapy followed by chemoradiation and surgery with and without cetuximab in patients with resectable esophageal cancer: a randomized, open-label, phase III trial (SAKK 75/08). <i>Annals of Oncology</i> , 2018, 29, 1386-1393.	0.6	76
48	The relationship of health/food literacy and salt awareness to daily sodium and potassium intake among a workplace population in Switzerland. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2018, 28, 270-277.	1.1	34
49	A short food literacy questionnaire (SFLQ) for adults: Findings from a Swiss validation study. <i>Appetite</i> , 2018, 120, 275-280.	1.8	87
50	Neoadjuvant radiotherapy combined with capecitabine and sorafenib in patients with advanced KRAS-mutated rectal cancer: A phase I/II trial (SAKK 41/08). <i>European Journal of Cancer</i> , 2018, 89, 82-89.	1.3	16
51	Impact of dose intensified salvage radiation therapy on urinary continence recovery after radical prostatectomy: Results of the randomized trial SAKK 09/10. <i>Radiotherapy and Oncology</i> , 2018, 126, 257-262.	0.3	19
52	Incidence of hypocalcemia in a non-inferiority phase III trial assessing prevention of symptomatic skeletal events (SSE) with denosumab (DN) administered every 4 weeks (q4w) versus every 12 weeks (q12w): SAKK 96/12 (REDUSE). <i>Annals of Oncology</i> , 2018, 29, viii609-viii610.	0.6	1
53	Tailored axillary surgery with or without axillary lymph node dissection followed by radiotherapy in patients with clinically node-positive breast cancer (TAXIS): study protocol for a multicenter, randomized phase-III trial. <i>Trials</i> , 2018, 19, 667.	0.7	73
54	Study design and baseline characteristics of a combined educational and environmental intervention trial to lower sodium intake in Swiss employees. <i>BMC Public Health</i> , 2018, 18, 421.	1.2	6

#	ARTICLE	IF	CITATIONS
55	Impact of a Surgical Sealing Patch on Lymphatic Drainage After Axillary Dissection for Breast Cancer: The SAKK 23/13 Multicenter Randomized Phase III Trial. <i>Annals of Surgical Oncology</i> , 2018, 25, 2632-2640.	0.7	9
56	In Regard to Pisansky et al. <i>International Journal of Radiation Oncology Biology Physics</i> , 2017, 97, 438-439.	0.4	1
57	Re: Radiation With or Without Antiandrogen Therapy in Recurrent Prostate Cancer. <i>European Urology</i> , 2017, 72, 319.	0.9	0
58	Importance and outcome relevance of central pathology review in prostatectomy specimens: data from the SAKK 09/10 randomized trial on prostate cancer. <i>BJU International</i> , 2017, 120, E45-E51.	1.3	13
59	OC-0125: Relevance of central pathology review in prostatectomy specimens: data from the SAKK 09/10 trial. <i>Radiotherapy and Oncology</i> , 2017, 123, S58-S59.	0.3	0
60	High thromboembolic event rate in patients with locally advanced esophageal cancer during perioperative therapy: A pre-planned analysis of the intergroup phase III trial SAKK 75/08. <i>Annals of Oncology</i> , 2017, 28, v217.	0.6	0
61	Is Dose-Intensified Salvage Radiation Therapy After Prostatectomy Beneficial?. <i>Journal of Clinical Oncology</i> , 2017, 35, 1490-1491.	0.8	1
62	Reply to C. Cozzarini et al. <i>Journal of Clinical Oncology</i> , 2016, 34, 1705-1706.	0.8	0
63	Orteronel Switch Maintenance Therapy in Metastatic Castration Resistant Prostate Cancer After First-Line Docetaxel: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial (SAKK 08/11). <i>Prostate</i> , 2016, 76, 1519-1527.	1.2	16
64	Haemoglobin and creatinine values as prognostic factors for outcome of concurrent radiochemotherapy in locally advanced head and neck cancers. <i>Strahlentherapie Und Onkologie</i> , 2016, 192, 552-560.	1.0	13
65	The effect of real-time electronic monitoring of patient-reported symptoms and clinical syndromes in outpatient workflow of medical oncologists: E-MO AIC, a multicenter cluster-randomized phase III study (SAKK 95/06). <i>Annals of Oncology</i> , 2016, 27, 324-332.	0.6	101
66	Preoperative versus postoperative docetaxel+cisplatin+fluorouracil (TCF) chemotherapy in locally advanced resectable gastric carcinoma: 10-year follow-up of the SAKK 43/99 phase III trial. <i>Annals of Oncology</i> , 2016, 27, 668-673.	0.6	42
67	Multidrug and toxin extrusion 1 and human organic cation transporter 1 polymorphisms in patients with castration-resistant prostate cancer receiving metformin (SAKK 08/09). <i>Prostate Cancer and Prostatic Diseases</i> , 2015, 18, 167-172.	2.0	12
68	Impact of weight loss on survival after chemoradiation for locally advanced head and neck Cancer: secondary results of a randomized phase III trial (SAKK 10/94). <i>Radiation Oncology</i> , 2015, 10, 21.	1.2	58
69	Acute Toxicity and Quality of Life After Dose-Intensified Salvage Radiation Therapy for Biochemically Recurrent Prostate Cancer After Prostatectomy: First Results of the Randomized Trial SAKK 09/10. <i>Journal of Clinical Oncology</i> , 2015, 33, 4158-4166.	0.8	99
70	Feasibility and acceptance of electronic monitoring of symptoms and syndromes using a handheld computer in patients with advanced cancer in daily oncology practice. <i>Supportive Care in Cancer</i> , 2014, 22, 2425-2434.	1.0	17
71	Metformin in Chemotherapy-naive Castration-resistant Prostate Cancer: A Multicenter Phase 2 Trial (SAKK 08/09). <i>European Urology</i> , 2014, 66, 468-474.	0.9	100
72	Development and Validation of a Medical Chart Review Checklist for Symptom Management Performance of Oncologists in the Routine Care of Patients With Advanced Cancer. <i>Journal of Pain and Symptom Management</i> , 2014, 48, 1160-1167.	0.6	6

#	ARTICLE	IF	CITATIONS
73	What can we learn from the ZOOM trial?. Lancet Oncology, The, 2013, 14, e388.	5.1	0
74	Real-Time Electronic Monitoring of Patient-Reported Symptoms and Syndromes (PRS): E-Mosaic, a Multicenter Phase iii Study (Sakk 95/06). Annals of Oncology, 2012, 23, ix462.	0.6	0
75	Depth of cure of resin composites: Is the ISO 4049 method suitable for bulk fill materials?. Dental Materials, 2012, 28, 521-528.	1.6	275